{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002706","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.102472+00:00","generated_at":"2026-05-16T10:54:47.103075+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bicycle Therapeutics outlines 2026 milestones; zelenectide pevedotin dose selection & approval pathway update in Q1","bullets":["Dose selection from Phase 2/3 Duravelo-2 trial and approval update for zelenectide pevedotin in mUC expected in Q1 2026","Additional EphA2 human imaging data for radiopharmaceuticals pipeline planned for first half of 2026","Initial data from Phase 1/2 Duravelo-3 trial in NECTIN4-amplified breast cancer expected in second half of 2026","Financial runway expected into 2028 to support execution of clinical and strategic priorities"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002706","json":"https://secwatch.observer/filing/0001104659-26-002706.json","markdown":"https://secwatch.observer/filing/0001104659-26-002706.md","text":"https://secwatch.observer/filing/0001104659-26-002706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926002706/0001104659-26-002706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926002706/tm262874d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:54:47.103075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}